Bone Biologics (BBLG) Projected to Announce Earnings on Friday

Bone Biologics (NASDAQ:BBLG) is projected to issue its results before the market opens on Friday, November 13th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Monday, October 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. On average, analysts expect Bone Biologics to post ($1.18) EPS for the current fiscal year and ($0.59) EPS for the next fiscal year.

Bone Biologics Price Performance

BBLG stock opened at $0.34 on Wednesday. Bone Biologics has a 12 month low of $0.32 and a 12 month high of $2.39. The company’s 50-day moving average price is $0.46 and its two-hundred day moving average price is $1.02.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research note on Thursday, October 22nd. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Bone Biologics

Bone Biologics Corporation is a biotechnology and medical device company focused on developing regenerative products for bone repair and spinal fusion. Its technology platform is based on NELL-1, a recombinant human protein designed to stimulate bone growth and support the formation of new bone. The company’s lead development programs combine NELL-1 with resorbable bone-graft scaffolds for use in orthopedic and spinal procedures. These products are intended to provide surgeons with alternatives or supplements to conventional bone-grafting approaches, with an initial emphasis on spinal fusion applications.